Dermata Therapeutics, Inc. (DRMA) Stock Price & Analysis

Dermata Therapeutics, Inc. (DRMA) rose 3.31% to USD 1.25 as of September 8, 2026 at 22:32 UTC, according to Nexqual real-time market data.

DRMA last closed at USD 1.25; the session ranged USD 1.21–1.31 on volume of 51,033 shares. Market capitalization is —, with a 52-week range of USD 0.95–6.23 (NCM). Source: Nexqual, September 8, 2026 at 22:32 UTC.

Key Statistics (as of September 8, 2026 at 22:32 UTC)

Technical Analysis (DRMA)

Nexqual's technical model rates DRMA "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 22:32 UTC.

From Dermata Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• The combination of a proprietary harvesting protocol, developed by our exclusive supplier, and the post-harvest processing procedures, produce an ingredient that we believe optimizes the mechanical components, which are silica microstructures also called spicules, as well as the organic components of Spongilla , while eliminating any harmful bacteria that could be found in many freshwater or marine sponges.
• With our proprietary harvesting protocols and manufacturing procedures, we are able to take Spongilla lacustric raw material and leverage the combination of evolution and scientific innovation to create a unique product we like to call, Bioneedle.
• Our product development strategy is centered on the scalable use of our proprietary Bioneedle as the foundation for any well-rounded skincare routine.
• BDS works by first topically applying our proprietary sponge powder to the treatment area wherein the mechanical Bioneedles penetrate the skin, thereby creating millions of microchannels into the dermis similar to the Image 4 below.

Partnerships

• One such location is the Volga River, where we have signed an exclusive supply agreement with one of the larger known suppliers of wild harvested Spongilla raw material for our Tome skincare line, which we believe provides us with a reliable source of our supply of Spongilla raw material for the foreseeable future.
• In February 2020, we signed an exclusive supply agreement with this supplier of Spongilla raw material .

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 22:32 UTC. This page is informational and not investment advice.